<?xml version="1.0" encoding="UTF-8"?>
<p id="p0040">Based on the Helsinki agreements, trials should not continue longer than necessary to answer the questions they are designed to address [
 <xref rid="bib1" ref-type="bibr">1</xref>]. Trials may be terminated because of overwhelming benefit, convincing evidence of harm or lack of benefit, or logistical problems that cannot be corrected. To accomplish their mission of safeguarding participant interests while enhancing trial integrity, the DMC meets periodically to review accumulating data on primary and secondary outcomes, safety, and quality of trial conduct. DMC members typically include those with expertise in clinical trials methods, biostatistics, the biology and clinical features of the disease, ethics, as well as expertise in the interventions being evaluated.
</p>
